Tuleviate: A Safer, Non-Addictive Analgesic

Potent Pain Relief Without the Risk of Addiction or Tolerance

Download One-Pager Download Slide Deck

Potent Pain Relief Without the Risk of Addiction or Tolerance

Tuleviate is a next-generation analgesic that selectively harnesses the body’s natural pain-relief pathways to deliver potent, long-lasting relief with a dramatically safer profile than traditional treatments. It is effective across a wide range of pain types, including acute, inflammatory, neuropathic, visceral, and postoperative pain.

Researchers

Why Tuleviate?

• Potent, Long-Lasting Pain Relief

Effective across acute, inflammatory, neuropathic, visceral, and postoperative pain models.

• Low Risk of Addiction

Demonstrates a non-addictive reward profile in preclinical models, unlike morphine or oxycodone.

• Minimized Withdrawal and Relapse

Blocks withdrawal symptoms and prevents relapse in models of opioid dependency.

• Reduced Tolerance Development

Maintains strong analgesic effects over time without the need for increasing doses.

• Avoids Activation of CGRP and Glial Cells

In contrast to chronic morphine, does not induce these two major causes of opioid tolerance and persistent pain.

• Safe and Well-Tolerated

Exhibits minimal respiratory depression, low toxicity, and a clean safety profile even at therapeutic doses.

Tuleviate provides significantly improved potency in visceral pain vs. morphine

Tuleviate does not induce drug-seeking behavior vs. morphine

Publications

Cyclic Glycopeptide Analogs of Endomorphin-1 Provide Highly Effective Antinociception in Male and Female Mice View
Endomorphin analog ZH853 shows low reward, tolerance, and affective-motivational signs of withdrawal, while inhibiting opioid withdrawal and seeking. View

Other resources

James Zadina Podcast Episode View
Title Country Date of Application Serial / ID Number Additional Notes
Tuleviate PCT US, Japan, Canada, Australia, and Hong Kong 07/08/2011 PCT/US2011/043306
Tuleviate EPO, US 05/01/2020 PCT/US20/31140 Method of use for treating opioid use disorder
Tuleviate NextGen (Glycosylated Analogs) Nationalized to US, AU, CA, JP, EPO 05/30/2023 PCT/US2023/23879 GLYCOSYLATED CYCLIC ENDOMORPHIN ANALOGS
Tuleviate NextGen (Glycosylated Analogs) US 11/26/2024 18/869,591
Tuleviate NextGen (Glycosylated Analogs) Australia 12/19/2024 2023279699
Tuleviate NextGen (Glycosylated Analogs) Canada 11/27/2024 3,257,674
Tuleviate NextGen (Glycosylated Analogs) Japan 11/29/2024
Tuleviate NextGen (Glycosylated Analogs) EPO 12/19/2024 23816646.6

Funding Sources

Explore a Partnership

Flexible collaboration models available — Sponsored Research, Co-Development, Licensing.

For inquiries, contact:
Elaine Hamm, PhD
Executive in Residence
Request a Meeting
Email me

X

Engage with Us

Flexible collaboration models available — Sponsored Research, Co-Development, Licensing.

For inquiries, contact:
Elaine Hamm, PhD
Executive in Residence
Email me